Letter to the EditorComparison of Two Assays for Serum 1,5-Anhydroglucitol
Section snippets
Acknowledgments
Dr. Selvin was supported by NIH/NIDDK grant K01 DK076595. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The authors thank the staff and participants of the ARIC study for their important contributions. Kyowa Medex provided in-kind support (reagents). The authors thank Dr. Kunihiro Matsushita
References (7)
- et al.
1, 5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes
Diab Res Clin Pract
(2009) Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine
J Diab Sci Technol
(2009)- Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, et al. Evaluation of serum 1,5 anhydroglucitol levels as a...
Cited by (22)
Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial
2021, Diabetes Research and Clinical PracticeCitation Excerpt :Limitations include the high prevalence of CVD (33%) due to trial eligibility criteria that included CVD history or > 1 CVD risk factor [13,14], and the single baseline measurement of 1,5-AG and the cardiac biomarkers. Biomarkers were measured after ∼ 15 years of freezer storage, however prior research suggests the validity and reliability of these measurements in long-term stored samples [16–19]. Our results suggest that monitoring cardiac markers provides more prognostic information regarding vascular risk than 1,5-AG.
Review of methods for detecting glycemic disorders
2020, Diabetes Research and Clinical PracticeCitation Excerpt :Earlier studies demonstrated that the plasma concentration of 1,5-AG could be a marker of previous (1–2 weeks) exposure to hyperglycemia above the glucose renal threshold, reflecting post-prandial hyperglycemic peaks [332,333]. Automated and quantitative 1,5-AG measurements can be performed using commercially available biochemical assay kits [334–336]. FDA approved this marker for monitoring intermediate-term glycemic control in those with diabetes and post-prandial hyperglycemia [337].
Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study
2018, AtherosclerosisCitation Excerpt :Fructosamine (Roche Diagnostics Corp, Indianapolis, IN, USA), glycated albumin (Asashi Kasei Lucica GA-L, Tokyo, Japan), and 1,5-AG (GlycoMark, Winston-Salem, NC) were measured in 2012–2013 in stored frozen serum using a Roche Modular P800 system [14,18]. Previous studies have shown these analytes to be reliable in long-term stored samples [19–21]. Age, gender, race, educational level, alcohol use, and smoking status were self-reported.
Clinical and forensic examinations of glycemic marker 1,5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry
2012, Forensic Science InternationalCitation Excerpt :Glycated hemoglobin (HbA1c) – although very stable after death [10] – is not a good indicator of glycemic control over shorter periods. For the determination of 1,5-AG in clinical serum samples, two commercially available enzymatic assays exist, the GlykoMark® assay [4] and the Determiner-l-1,5-AG® (Kyowa Medex, Japan) [11] which were compared recently, both showing comparable results [12]. In these assays, a hydrogen peroxide by-product is detected colorimetrically using a standard peroxidase assay after the oxidation of 1,5-AG to 1,5-anhydrofuctose by pyranose oxidase.
Development of a simple and flexible enzyme-based platform for the colorimetric detection of multiple biomarkers in non-conventional biofluids
2022, Journal of Chemical Technology and Biotechnology